BSP completes HyperQ technology clinical study on CAD BSP Biological Transmission Processing Ltd. , which develops and manufactures items for the noninvasive, accurate analysis of Coronary Artery Disease , lately announced the effective completion of a thorough clinical study evaluating the functionality of the business’s HyperQ technology in diagnosing CAD. Articles describing the study and its own results was approved for publication in the prestigious American Journal of Cardiology silagra100rx.com http://silagra100rx.com . The scholarly study recruited 996 patients and compared the clinical performance of HyperQ vs. Typical ECG for the recognition of Coronary Artery Disease , using nuclear imaging as the gold regular. The study was carried out in two main medical centers in Israel – Assuta INFIRMARY and Sheba INFIRMARY, and was headed by Dr.

In addition, it represents a significant step of progress in our dedication to provide and execute against our differentiated and concentrated BioPharma technique.’ ‘For the very first time, oncologists possess cure option for individuals with unresectable or metastatic melanoma that is verified in a randomized Stage 3 scientific trial to significantly expand the lives of individuals,’ stated Steven J. O’Day, M.D., Chief of Director and Analysis of the Melanoma System at The Angeles Clinic and Research Institute, California, and an investigator of the pivotal trial. ‘Actually, the Kaplan-Meier curve out of this scholarly study suggests an extended survival benefit for a few patients.’ Median general survival was 10 a few months for YERVOY , six months for gp100 and 10 weeks for YERVOY + gp100, with p-values of 0.0026 for YERVOY and 0.0004 for YERVOY + gp100 vs gp100, respectively.